The first international guidance on antithrombotic therapy in the elderly came from the
European Society of Cardiology Working Group on Thrombosis in 2015. This same group …

Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Aims Dual-antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is the
standard treatment for patients with acute coronary syndrome (ACS) undergoing …

Precision medicine is a medical model that proposes the customization of medical
treatments to the individual patient, as opposed to a one-drug-fits-all model. Such a …

Background: The benefit of dual antiplatelet therapy (DAPT) for reducing ischemic events is
greatest in the early period of acute coronary syndrome, and recent randomized controlled …

Dual antiplatelet therapy (DAPT) represents the standard of care for patients undergoing
percutaneous coronary intervention (PCI). Increasing evidence indicates that a “one-size-fits …

Introduction Platelets play a key role in arterial thrombosis and antiplatelet therapy is pivotal
in the treatment of cardiovascular disease. Current antiplatelet drugs target different …

Platelets have a crucial role in haemostasis and atherothrombosis. Pharmacological control
of platelet hyper-reactivity has become a cornerstone in the prevention of thrombo …

Background In TAILOR‐PCI, genotype‐guided selection of P2Y12 inhibitors after
percutaneous coronary intervention did not significantly reduce the risk of ischemic events at …

The synergistic blockade of the key platelet signaling pathways of cyclooxygenase-1
blockade and P2Y12 signaling by combining aspirin plus a potent P2Y12 inhibitor …